Objectives: To verify the clinical validity and accuracy of DNA microarray kit for genetic testing of 15 target deafness mutations.Methods: The whole blood samples from 420 outpatients or inpatients with or without deafness were tested using sequencing and DNA microarray kit which is authenticated by SFDA.Among them, 103 cases were wild type and 317 cases carrying mutations including 50 enlarged vestibular aqueduct syndrome (EVAS) patients.